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Estrogens play a major role in the modulation of
energy balance through central and peripheral
actions. Here, we demonstrate that central action of
estradiol (E2) inhibits AMP-activated protein kinase
(AMPK) through estrogen receptor alpha (ERa)
selectively in the ventromedial nucleus of the hypo-
thalamus (VMH), leading to activation of thermogen-
esis in brown adipose tissue (BAT) through the
sympathetic nervous system (SNS) in a feeding-inde-
pendent manner. Genetic activation of AMPK in the
VMH prevented E2-induced increase in BAT-medi-
ated thermogenesis and weight loss. Notably, fluctu-
ations in E2 levels during estrous cycle alsomodulate
this integrated physiological network. Together,
these findings demonstrate that E2 regulation of the
VMH AMPK-SNS-BAT axis is an important determi-
nant of energy balance and suggest that dysregula-
tion in this axis may account for the common
changes in energy homeostasis and obesity linked
to dysfunction of the female gonadal axis.
INTRODUCTION
Ovarian estrogens play a major role in the regulation of energy
homeostasis (Gao and Horvath, 2008; Hill et al., 2013; Mau-
vais-Jarvis et al., 2013). Decreased levels of estradiol (E2) after
menopause or ovariectomy (OVX) are also associated with hy-perphagia, reduced energy expenditure, andweight gain (Rogers
et al., 2009; Mauvais-Jarvis et al., 2013). In turn, E2 replacement
therapy prevents OVX-induced obesity by decreasing feeding
and increasing energy expenditure (Gao and Horvath, 2008;
Finan et al., 2012; Mauvais-Jarvis et al., 2013). Likewise, hor-
mone replacement therapy reverses the development of obesity
and metabolic dysfunctions in postmenopausal women (Wren,
2009; Mauvais-Jarvis et al., 2013). Studies have also suggested
variations in meal size and body weight in rats depending on the
stage of the estrous cycle (Tritos et al., 2004), as well as during
pregnancy and lactation (Garcı´a et al., 2003).
Genetic models of loss of function of estrogen receptors (ERs),
which are widely expressed in the hypothalamus (Shughrue
et al., 1997), have demonstrated that mice with global or brain-
specific targeted disruption of ER alpha (ERa) are obese, as a
consequence of hyperphagia and hypometabolism (Heine
et al., 2000; Xu et al., 2011). Similarly, mice and patients deficient
for the aromatase enzyme, whichmediates the conversion of an-
drogens to estrogens, develop obesity (Grumbach and Auchus,
1999; Jones et al., 2000; Jones et al., 2001). Interestingly, estro-
gens display a nucleus-specific action within the hypothalamus
to modulate energy balance, particularly within the arcuate
(ARC) and ventromedial (VMH) nuclei. VMH-specific delivery of
adeno-associated viral vectors silencing ERa in mice and rats
leads to marked obesity, impaired glucose tolerance, and
reduced energy expenditure (Musatov et al., 2007). Of note,
these genetic manipulations did not alter food intake,
indicating that estrogens actions in the VMH modulate specif-
ically energy expenditure. In keeping with this, female mice lack-
ing ERa in hypothalamic steroidogenic factor-1 (SF1) neurons
of the VMH exhibit reduced energy expenditure and brown adi-
pose tissue (BAT)-mediated thermogenesis, leading to obesity,Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc. 41
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ERa in proopiomelanocortin (POMC) neurons of the ARC leads
to hyperphagia without changes in energy expenditure (Xu et al.,
2011). Finally, concomitant deletion of ERa from both SF1 and
POMC neurons recapitulates both phenotypes, causing hypo-
metabolism, hyperphagia, and severe obesity (Xu et al., 2011).
Despite this evidence, the molecular and cellular events medi-
ating E2-induced negative energy balance and BAT thermogen-
esis remain elusive. Thus, the aim of this study was to investigate
the hypothalamic mechanism mediating E2-induced thermo-
genesis. We show that central E2 regulates BAT thermogenesis
through ERa and activation of the sympathetic nervous system
(SNS) by modulating hypothalamic AMP-activated protein ki-
nase (AMPK), specifically in the VMH.
RESULTS
Peripheral E2 Induces Negative Energy Balance
OVX rats gained significantly more weight and developed a
marked hyperphagia (Figures 1A and 1B). Subcutaneous (SC)
treatment of OVX rats with E2 induced a marked reduction in
body weight and food intake (Figures 1A and 1B) leading to a
state of negative energy balance (Figure S1A available online).
OVX rats showed the expected increase in serum luteinizing hor-
mone (LH) and decrease in circulating E2 levels (confirming the
efficiency of the OVX procedure), while SC E2 treatment recover
both parameters to physiological levels (Figures S1B and S1C).
For this reason, and in order to avoid a possible interference of
fluctuations of ovarian E2 production during the estrous cycle,
we used OVX rats in all the experiments (with the exception of
Figures 7 and S7A–S7C, where intact rats were used).
The anorectic effect of E2 was found to be associated with
decreased NPY mRNA and increased POMC mRNA levels in
the ARC of OVX rats treated with E2 (Figures 1C and 1D). E2-
treated rats showed decreased phosphorylated levels of AMPKa
(pAMPKa) and ACCa (pACCa, which is inactive when phosphor-
ylated) in the whole hypothalamus (Figure 1E). Consistent with
ACC activation, we found that E2 increased the hypothalamic
malonyl-CoA levels (Figure 1F). To establish the functional
dependence of E2’s actions on hypothalamic AMPK and
malonyl-CoA levels, we investigated whether pharmacological
activation of central AMPK could reverse the anorectic effects
of E2. Intracerebroventricular (ICV) administration of the AMPK
activator AICAR decreased hypothalamic malonyl-CoA concen-
tration (Figure 1G) and reversed the hypophagia observed in rats
treated with E2 (Figure 1H).
E2 Modulates the Thermogenic Program in BAT
Independently of Food Intake
To dissect the relative contribution of the anorectic effect of E2 to
its impact on energy homeostasis, a group of vehicle-treatedFigure 1. Effect of SC E2 on Energy Balance
(A–F) (A) Body weight change, (B) daily food intake, (C) in situ hybridization autora
autoradiographic images (left panel) and hypothalamic levels of proteins of AMPK
OVX rats SC treated with vehicle or E2.
(G and H) (G) Hypothalamic malonyl-CoA levels and (H) food intake of OVX rat
bars represent SEM; n = 8–16 animals per experimental group. 3V: third ventric
ICV; #p < 0.05 E2 SC vehicle ICV versus E2 SC AICAR ICV; ###p < 0.001 versuspair-fed rats (i.e., received the average amount of food eaten
by the E2-treated rats the day before) was studied. SC adminis-
tration of E2 to OVX rats decreased body weight largely
exceeding that of pair-fed OVX rats, indicating a food-indepen-
dent weight loss (Figures 2A and 2B). SC administration of
E2 increased the mRNA expression or protein content of
thermogenic markers, such as uncoupling protein-1 (UCP1),
peroxisome-proliferator-activated receptor-gamma coactivator
1 alpha (PGC1a) and beta (PGC1b) in the BAT (Figures 2C and
2D), while no changes in browning markers (Walde´n et al.,
2012; Ohno et al., 2012; Fisher et al., 2012) were detected in
white adipose tissue (WAT) (Figure S2A). Peripheral administra-
tion of E2 induced a slight upregulation of the thermogenic
program in liver but not in skeletal muscle (Figures S2B and
S2C). No changes in inflammatory markers were detected in
muscle either (Figure S2C).
Next, we examined the possibility that these effects of E2 are
centrally mediated. We found that ICV administration of E2
induced weight loss that was significantly larger than that
observed in OVX pair-fed animals (Figures 2E and 2F). Consis-
tently, the mRNA expression or protein content of UCP1,
PGC1a, and PGC1b was markedly increased in BAT of ICV E2-
treated rats when compared to both vehicle-treated and pair-
fed animals (Figures 2G and 2H), whereas no changes in
browning markers were found in WAT (Figure S2D). No increase
in the expression of thermogenic or inflammatory markers was
detected in the liver or muscle after ICV E2 administration (Fig-
ures S2E and S2F).
Central E2 Increases Energy Expenditure and SNS
Activity and Inhibits Hypothalamic AMPK
ICV E2-treated (5 nmol) rats showed decreased weight (Fig-
ure 3A), anorexia (Figure 3B), as well as a significantly higher
body temperature (Figure 3C) and energy expenditure (EE) (Fig-
ure 3D) associated with reduced respiratory quotient (RQ) (which
indicates increased lipid mobilization; Figure 3E) and locomotor
activity (LA) (Figure 3F), which overall promote a negative energy
balance (Figure S3A). Notably, a single ICV administration of E2
caused a marked increase in BAT sympathetic nerve traffic re-
corded directly by microneurography (Figure 3G). ICV E2 also
decreased AMPK activation in the mediobasal hypothalamus
(MBH) (Figure 3H).
Central E2 Induces BAT Thermogenesis through
the SNS
In order to further investigate whether ICV E2-induced increase
in thermogenic markers correlated with changes in BAT thermo-
genesis, we used thermographic imaging analysis (Martı´nez de
Morentin et al., 2012; Whittle et al., 2012). Of note, a lower ICV
E2 dosage was used in these experiments. A total of 1 nmol of
ICV E2 induced a marked weight loss, anorexia, and an increasediographic images, (D) Npy and PomcmRNA levels in the ARC, (E) western blot
pathway (right panel), and (F) hypothalamic malonyl-CoA levels of OVX rats and
s SC treated with vehicle or E2 and ICV treated with vehicle or AICAR. Error
le; *, ** and ***p < 0.05, 0.01, and 0.001 vs. OVX E2 SC or vehicle SC vehicle
sham or E2 SC vehicle ICV versus E2 SC AICAR ICV.
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Figure 2. Effect of SC and ICV E2 on BAT Thermogenic Markers
(A–D) (A) Bodyweight change, (B) daily food intake, (C) mRNA expression profile in the BAT, and (D) protein levels (upper panel) andwestern blot autoradiographic
images of BAT UCP1 protein (lower panel) of OVX rats treated with vehicle or E2 SC and pair-fed (PF) rats.
(E–H) (E) Bodyweight change, (F) daily food intake, (G) mRNA expression profile in the BAT, and (H) protein levels (upper panel) and western blot autoradiographic
images of BAT UCP1 protein (lower panel) of OVX rats treated with vehicle or E2 ICV (5 nmol) and pair-fed rats. Error bars represent SEM; n = 8–20 animals per
experimental group. *, **, and ***p < 0.05, 0.01, and 0.001 versus vehicle (SC or ICV); #, ##, and ###p < 0.05, 0.01, and 0.001 versus E2 (SC or ICV).
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ture was associated with elevated UCP1 protein levels in BAT
(Figure 4B) and a significant rise in the temperature of the skin
surrounding interscapular BAT (Figure 4C), indicating elevated
thermogenesis. No changes were detected in WAT browning
program after ICV treatment with E2 (Figure S4A). The effects
evoked by ICV E2 are not related to leakage of E2 from the
cerebrospinal fluid, because circulating levels of E2 remain
unchanged after ICV treatment (Figure S4B).
AMPK in VMHplays amajor role in themodulation of BAT ther-
mogenesis (Lo´pez et al., 2010; Martı´nez deMorentin et al., 2012;
Whittle et al., 2012). Thus, we aimed to investigate whether ICV
E2 elicits changes in VMH AMPK signaling with ARC samples
used as control. The specificity of the VMH and ARC dissections
was confirmed by analyzing the mRNA of specific markers,
namely SF1 and POMC, respectively (Figure S4C). We found
that ICV administration of 1 nmol of E2 elicited similar changes
to those observed in the MBH after 5 nmol of the hormone,
namely decreased VMH AMPK activity (Figure 4D). ICV adminis-
tration of 0.5 nmol of E2 also induced weight loss, anorexia,
increased UCP1 in BAT, and decreased hypothalamic AMPK
signaling (data not shown). No changes were found in the ARC
AMPK pathway after ICV E2 injections (Figure S4D). Of note,
the effect of ICV E2 administration was not related to increased
inflammatory responses in the VMH (where, in fact, inflammatory
markers showed reduced expression) (Figure S4E) or muscle
(Figure S4F).44 Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc.Given that ICV E2 induced a marked increase in the activity of
the SNS subserving BAT, we aimed to investigate whether
adrenergic receptors blockade impact the central effect of ICV
E2 on BAT thermogenic program. Central administration of
1 nmol of E2 was reversed (in a feeding-independent manner)
by pharmacological blockade of beta 3 adrenergic receptor
(b3-AR) with the specific antagonist SR59230A (Lo´pez et al.,
2010) (Figures 4E and 4F). The increase in body weight induced
by SR59230A was associated with appropriate reversal of ICV
E2-induced activation of temperature (Figure 4G) and BAT
UCP1 expression (Figure 4H).
E2 within the VMH Regulates Hypothalamic AMPK and
BAT Thermogenic Program
We performed stereotaxic administration of E2 into the VMH or
the ARC. To assess the effects of E2 in both hypothalamic nuclei,
we performed anatomical analysis of the injection routes, as well
as a combined injection of vehicle or E2 with fluorescein-isothio-
cyanate (FITC), which allowed us to control the diffusion of the
treatment. Both VMH and ARC injections were specific, and
the treatment did not spread to other hypothalamic areas (Fig-
ure 5A); moreover, no damage in VMH or ARC structures was
found when the sections were stained with toluidine blue (Fig-
ure S5A). We found that administration of E2 in the VMH, but
not in the ARC, induced a significant rise in temperature (Fig-
ure 5B) associated with an upregulation of BAT UCP1 at both
mRNA and protein levels (Figure 5C). In order to confirm these
Figure 3. Effect of ICV E2 on Energy Balance, BAT Activation, and Hypothalamic AMPK Pathway
(A–H) (A) Body weight change, (B) daily food intake, (C) core temperature, (D) energy expenditure (EE) (cumulative in left panel and total in right panel), (E)
respiratory quotient (RQ) (cumulative in left panel and total in right panel), (F) locomotor activity (LA) (cumulative in left panel and total in right panel), (G) BAT
sympathetic nervous activity (SNA) tracings (upper panel) and time-course of BAT SNA response (lower panel), and (H) western blot autoradiographic images (left
panel) and hypothalamic protein levels of proteins of the AMPK pathway (right panel) of OVX rats ICV treatedwith vehicle or E2 (5 nmol). Error bars represent SEM;
n = 6 (SNA recordings) or 8–12 animals per experimental group. *, **, and ***p < 0.05, 0.01, and 0.001 vs. vehicle ICV.
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which recapitulated the E2-induced increase in BAT UCP1
(Figure S5C). To better control for the specificity of VMH admin-
istration, we performed ‘‘missed’’ E2 injections, in ‘‘VMH-neigh-
boring’’ areas without affecting the VMH (Figure S5D). Our
anatomical data showed that when VMH was not ‘‘hit’’ (as indi-
cated by the absence of FITC in this nucleus), no changes in
UCP1 expression in the BAT were detected (Figure S5E). This
evidence indicates that the effect of E2 on BAT thermogenic pro-
gram is specific of the VMH and it is not related to E2 spreading
to adjacent areas. In line with the temperature and anatomical
data, administration of E2 into the ARC did not affect the expres-
sion of thermogenic markers in the BAT (Figure 5D). In addition,
these effects are not related to leakage or diffusion of central E2
from the brain, because circulating levels of E2 remained un-
changed after VMH and ARC injections (Figure S5F).
We then assessed the effect of VMH and ARC E2 injection on
the central mechanism modulating BAT thermogenic program.Rats receiving E2 in the VMH (but not ARC) displayed a signifi-
cant increase in neuronal activation in the inferior olive (IO) and
the raphe pallidus (RPa), as defined by c-FOS staining (Fig-
ure 5E). The RPa and IO have been involved in the sympathetic
activation of BAT in response to cold (Shibata et al., 1999; Uno
and Shibata, 2001; Cano et al., 2003; Cannon and Nedergaard,
2004). We also analyzed the effect of specific stereotaxic injec-
tion of E2 on the AMPK pathway in the VMH versus ARC. The
administration of E2 into the VMH decreased the protein levels
of pAMPK and pACC in this nucleus (Figure 5F; left images
and graph). In contrast, no effect was detected on AMPK
pathway when E2 was microinjected into the ARC (Figure 5F;
right images and graph). AMPK is activated by phosphorylation
of upstream kinases. The main upstream AMPK kinases are
the tumor suppressor LKB1 and Ca2+/calmodulin-dependent
protein kinase kinase alpha and beta (CaMKKa and CaMKKb),
which phosphorylate AMPK at Thr172; AMPK phosphorylation
levels are also regulated by protein phosphatase-2Ca (PP2Ca)Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc. 45
Figure 4. Effect of ICV E2 on Energy Balance and the VMH AMPK-SNS-BAT Axis
(A–D) (A) Body weight change (left panel), daily food intake (middle panel), and core temperature (right panel); (B) protein levels (upper panel) and western blot
autoradiographic images of BAT UCP1 protein (lower panel); (C) infrared thermal images (left panel) and quantification of temperature of the skin surrounding
interscapular BAT (right panel); and (D) western blot autoradiographic images (left panel) and VMH protein levels of proteins of the AMPK pathway (right panel) of
OVX rats ICV treated with vehicle or E2 (1 nmol).
(E–H) (E) Body weight change, (F) daily food intake, (G) core temperature, and (H) western blot autoradiographic images of BAT UCP1 protein (left panel) and
UCP1 protein levels (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol), previously SC treated with the b3-AR-antagonist SR59230A for 2 days. Error
bars represent SEM; n = 7–12 animals per experimental group. * and ***p < 0.05 and 0.001 versus vehicle ICV or vehicle ICV vehicle SC; # and ##p < 0.05 and 0.01
versus E2 ICV vehicle SC.
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specific VMH E2 injection, the protein levels of CaMKKa and
pLKB1 were decreased, whereas the levels of PP2Ca were
increased in the VMH (Figure 5G). Consistent with these data,
AMPK phosphorylation status was also reduced 2 hr after E2
treatment in the VMH (Figure S5G). Finally, E2 caused no
changes in the activity of PI3K and AKT signaling in the VMH
(just an increase in total AKT levels; Figure 5H), and as previously
described (Gao et al., 2007), E2 induced amarked increase in the
pSTAT3 levels in the VMH (Figure 5H).
Activation of AMPK in the VMH Reverses the Central
Action of E2
To elucidate the contribution of AMPK activity in the VMH to
the thermogenic program in the BAT after E2 central treat-
ment, adenoviruses encoding constitutively active AMPKa-CA,
together with GFP or control adenovirus expressing GFP alone
(Minokoshi et al., 2004; Lo´pez et al., 2008, 2010; Martı´nez de46 Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc.Morentin et al., 2012; Whittle et al., 2012), were injected stereo-
taxically into the VMH or the ARC of OVX rats treated with vehicle
or E2. Infection efficiency was assessed by (a) expression of GFP
in the VMH (Figure 6A) or in the ARC (Figure 6E) and (b) increased
phosphorylation of ACCa (Figure S6A). Quantification analyses
showed that when the injections were directed to the VMH, the
vast majority of GFP-positive cells (98.4%) reside in the VMH
(Figure S6B). On the other hand, when the ARC was targeted,
we achieved a similar level of specificity with 95% of GFP-
positive cells in this nucleus (Figure S6C). Administration of
AMPKa-CA adenoviruses into the VMH reversed the weight
loss in OVX rats treated with E2 (Figure 6B) with no alteration in
food intake (Figure 6C). Overexpression of AMPKa-CA in the
VMH was also associated with a reduction in expression of
UCP1, PGC1a, and PGC1b in the BAT, as well as reduced
core temperature, of OVX rats treated with E2 (Figure 6D). This
effect was VMH specific, since AMPKa-CA adenoviruses in-
jected into the ARC of OVX rats treated with E2 caused a slight
Figure 5. Effect of E2 within the VMH or ARC on BAT Thermogenic Markers, Central SNS Outflow, and Hypothalamic AMPK Pathway
(A) Representative photomicrographs of brain sections showing the injection route enclosed in a red rectangle, precisely placed in the VMH or ARC (103, left
panel), and immunofluorescence of brain sections (203) showing the presence of the dye (FITC) after comicroinjection with E2 within the VMH or the ARC.
(B and C) (B) Core temperature and (C) mRNA expression profile in the BAT (left panel), protein levels (right-upper panel), and western blot autoradiographic
images of BAT UCP1 (right-lower panel) of OVX rats stereotaxically treated with vehicle or E2 within the VMH.
(D) mRNA expression profile in the BAT (left panel), protein levels (right-upper panel), and western blot autoradiographic images of BAT UCP1 (right-lower panel)
of rats stereotaxically treated with vehicle or E2 within the ARC.
(E) Representative photomicrographs (upper: 1.253, lower 103) showing immunohistochemistry of c-FOS (left panel) and c-FOS immunoreactive (IR) (right
panel) cells in the inferior olive (IO) and the raphe pallidus (RPa) nuclei of OVX rats stereotaxically treated with vehicle or E2 within the VMH or ARC.
(F) Western blot autoradiographic images (left panels) and levels of proteins of the AMPK pathway (right panels) in the VMH or ARC of OVX rats stereotaxically
treated with vehicle or E2 within the VMH (left images and graph) and the ARC (right images and graph); thus, when injection of E2 was performed in the VMH, the
AMPK pathway was analyzed in the VMH, and when injection of E2 was performed in the ARC, the AMPK pathway was analyzed in the ARC.
(G and H) Western blot autoradiographic images (left panels) and protein levels (right panels) of (G) upstream kinases of AMPK and (H) PI3K/AKT pathway (left
images and graph) and pSTAT3/STAT (right images and graph) in the VMH of OVX rats stereotaxically treated with vehicle or E2 within the VMH. Error bars
represent SEM; n = 5 (c-FOS analysis) or 7–8 animals per experimental group. Gi: gigantocellular reticular nucleus; IO: inferior olive; ME: median eminence; py:
pyramidal tract; RPa: raphe pallidus nucleus. *, ** and ***p < 0.05, 0.01, and 0.001 vs. vehicle VMH. In (A), it is important to note that the figure oversimplifies the
protocol, since injections were given bilaterally.
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(Figure 6F), which was associated with increased feeding (Fig-
ure 6G) but unaltered expression of thermogenic markers in
the BAT (Figure 6H).
A particular feature of adenoviral experiments is that adminis-
tration of AMPKa-CA had no effect on body weight per se in OVX
animals treated with vehicle. A possible explanation for this is
that AMPK was already maximally activated in the OVX state
(data not shown). Thus, we determined whether chronic inactiva-tion of AMPK in the VMH or the ARC can alter markers of BAT
activation of OVX rats. Stereotaxic delivery of a dominant-
negative isoform of AMPKa (AMPKa-DN) (Figure S6A) into the
VMH, but not into the ARC, caused feeding-independent
weight loss that began on the day following the injection (Figures
S6D, S6E, S6G and S6H). Administration of AMPKa-DN into
the VMH, but not into the ARC, of OVX rats increased the ex-
pression of UCP-1, PGC1a, and PGC1b in the BAT (Figures
S6F and S6I).Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc. 47
Figure 6. Effect of Activation of Hypothalamic AMPK on the Central Actions of E2 on Energy Balance
(A) Representative immunofluorescence (203) with anti-GFP antibody showing GFP expression in the VMH of OVX rats treated with adenoviruses encoding
AMPKa-CA within the VMH.
(B–D) (B) Body weight change, (C) daily food intake, and (D) mRNA expression profile in the BAT (left panel) and core temperature (at 24 hr, right panel) of OVX rats
SC treated with vehicle or E2 (VMH in [D], right) and stereotaxically treated with GFP or AMPKa-CA adenoviruses within the VMH.
(E) Representative immunofluorescence (203, left panel, and 403, right panel) with anti-GFP antibody showing GFP expression in the ARC of rats treated with
adenoviruses encoding AMPKa-CA within the ARC.
(F–H) (F) Body weight change, (G) daily food intake, and (H) mRNA expression profile in the BAT of OVX rats SC treated with vehicle or E2 and stereotaxically
treated with GFP or AMPKa-CA adenoviruses within the ARC. Error bars represent SEM; n = 8–17 animals per experimental group. 3V: third ventricle; *, **, and
***p < 0.05 and 0.01 vs. vehicle GFP VMH or ARC; #, ## and ### p < 0.05 and 0.01versus E2 GFP VMH or ARC.
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through ERa
To gain further insight into the physiological effects of endoge-
nous E2 on the aforementioned VMH AMPK-SNS-BAT axis, we
studied female rats at diestrus that display low-to-mid circulating
levels of E2, in contrast to preovulatory animals with peak E2
concentrations (Figures S1B and 7A). Diestrus rats had higher
core temperature (Figure 7A) and BAT UCP1 protein levels (Fig-
ure 7B) than OVX rats, as well as decreased AMPK signaling
in the VMH (Figure 7C). Consistent with these data, ICV
administration of the combined ERa-b antagonist ICI 182.780
(Move´rare-Skrtic et al., 2014) to intact female rats induced
feeding-independent weight gain (Figure S7A) in association48 Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc.with decreased UCP1 expression in the BAT (Figure S7B) and
increased AMPK signaling in the VMH (Figure S7C).
ICV injections of the specific ERa antagonist MPP (Sun et al.,
2002) to intact female rats induced weight gain and a tendency
for food intake to increase (Figure 7D) in association with
decreased BAT UCP1 expression (Figure 7E) and increased
AMPK signaling in the VMH (Figure 7F). In keeping with this,
ICV administration of the specific ERa agonist PPT (Sa´nchez-
Criado et al., 2004, 2006; Roa et al., 2008) to OVX rats recapitu-
lated the effects of E2 by eliciting weight loss and anorexia
(Figure S7D), associated with increased UCP1 expression in
BAT (Figure S7E) and reduced AMPK signaling in the VMH (Fig-
ure 7F). VMH administration of a lentivirus encoding an shRNA
Figure 7. Effect of Physiological Levels of E2 and Pharmacological and Genetic Manipulation of ERa on the VMH AMPK-SNS-BAT Axis
(A–C) (A) Serum E2 levels (left panel) and core temperature (right panel), (B) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1
protein (lowerpanel), and (C)westernblot autoradiographic images (left panel) and levelsofproteinsofAMPKpathway in theVMH(rightpanel) of diestruscycled rats.
(D–F) (D) Body weight change (left panel) and daily food intake (right panel), (E) protein levels (upper panel) and western blot autoradiographic images of BAT
UCP1 protein (lower panel), and (F) western blot autoradiographic images (left panel) and levels of proteins of AMPK pathway in the VMH (right panel) of intact rats
ICV treated with the specific ERa antagonist MPP.
(G–I) (G) Body weight change (left panel) and daily food intake (right panel), (H) protein levels (upper panel) and western blot autoradiographic images of BAT
UCP1 protein (lower panel), and (I) western blot autoradiographic images (left panel) and levels of proteins of AMPK pathway in the VMH (right panel) of intact
rats stereotaxically treated within the VMH with lentivirus encoding short hairpin RNA of the ERa. Error bars represent SEM; n = 7–8 animals per experimental
group. *, **, and ***p < 0.05, 0.01, and 0.001 versus OVX, vehicle ICV, or GFP VMH.
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without changes in feeding behavior (Figure 7G) and simulta-
neous decrease in UCP1 expression in BAT (Figure 7H) and an
increase in AMPK signaling in the VMH (Figure 7I). Conversely,
overexpression of a wild-type isoform of ERa in the VMH of
OVX rats, using adenoviral vector, induced feeding-independent
weight loss (Figure S7G) in association with increased BAT
UCP1 expression (Figure S7H) and decreased AMPK signaling
in the VMH (Figure S7I).
DISCUSSION
This study identifies a link between the effects of E2 on hypotha-
lamic AMPK and BAT thermogenesis. Specifically, we show thatactivation of BAT thermogenic program and subsequent energy
expenditure depends on ERa-mediated inactivation of VMH
AMPK. Overall, these results offer a physiological mechanism,
via the energy sensor AMPK, for the central actions of E2 on
ERa that is of relevance in linking the changes in energy balance
and obesity-associated alterations in the gonadal axis.
Conditions in which ovarian estrogens are lacking, such as
OVX or menopause, are associated with hyperphagia and
decreased caloric expenditure that results in a positive energy
balance leading to obesity. Estrogen replacement reverts this
phenotype both in women and female rodents (Carr, 2003;
Gao and Horvath, 2008; Rogers et al., 2009; Wren, 2009; Finan
et al., 2012; Mauvais-Jarvis et al., 2013). Recent evidence indi-
cates that hypothalamic kisspeptin/neurokinin B/dynorphinCell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc. 49
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E2 modulation of body temperature (Mittelman-Smith et al.,
2012; Rance et al., 2013). Also, genetic models have shown
that some of the actions of estrogens on energy homeostasis
are centrally mediated through activation of ERa in key hypotha-
lamic nuclei, such as the ARC and the VMH (Musatov et al., 2007;
Xu et al., 2011). In this regard, compelling data have demon-
strated that E2, the most important ovarian estrogen, inhibits
feeding in a leptin-independent (but STAT3-dependent) manner,
acting on POMC, NPY, and melanin-concentrating hormone
(MCH) neurons in the hypothalamus (Mystkowski et al., 2000;
Gao et al., 2007). Furthermore, it has been proposed that E2
modulates ghrelin signaling and that this endocrine interaction
may account for important sex differences in the regulation of
food intake (Clegg et al., 2007). However, E2 action on feeding
does not explain the entire change in body weight, as shown
here in experiments assessing the effect of estrogens in pair-
fed animals.
Recent literature indicates that hypothalamic AMPK pathway
is a central regulator of energy homeostasis that acts by control-
ling both feeding and energy dissipation (Minokoshi et al., 2004;
Lo´pez et al., 2008, 2010; Andrews et al., 2008; Martı´nez de Mor-
entin et al., 2012; Whittle et al., 2012). Therefore, we hypothe-
sized that E2-induced actions on energy balance could be
mediated by hypothalamic AMPK. Our data showed that periph-
eral administration of E2 induced a negative energy balance in
obese and hyperphagic OVX rats, associated with inactivation
of AMPK signaling and increased malonyl-CoA levels in the
hypothalamus. Notably, central pharmacological activation of
AMPK, using AICAR, was able to restore hypothalamic
malonyl-CoA concentration and reversed the anorectic effect
evoked by E2 administration. Overall, these data indicate that
hypothalamic AMPK mediated the actions of E2 on energy bal-
ance. These results are in line with previous evidence suggesting
an anabolic role for AMPK in the hypothalamus, which is in
contrast with its peripheral catabolic function (Minokoshi et al.,
2002; Minokoshi et al., 2004; Narkar et al., 2008). Of note, the
effects of peripherally administered E2 were recapitulated by
its central injection. ICV administration of E2 promoted a state
of negative energy balance, characterized by hypophagia,
increased energy expenditure, and BAT thermogenesis, leading
to marked weight loss. This effect was associated with a robust
decrease in hypothalamic AMPK signaling, neuronal activation in
RPa and IO (two nuclei which have been functionally linked to the
regulation of BAT thermogenesis) (Morrison, 1999; Shibata et al.,
1999; Uno and Shibata, 2001; Cano et al., 2003; Morrison et al.,
2014), and increased SNS tone to BAT. While based on the liter-
ature we do believe that our activation (c-FOS) data in IO and
caudal RPa are related to BAT activity, we cannot rule out the
possibility that at least part of the responses observed might
be related to other functions, such as motor control, as previ-
ously described (Welsh and Llina´s, 1997; Apps, 1999). Impor-
tantly, the above effects are reversed by pharmacological
blockage of b3-AR and appear to derive from VMH-specific
actions of E2, so that the impact of E2 on BAT thermogenesis
derives from its ability to modulate AMPK activity in the VMH.
Interestingly, when E2 was given in the neighboring ARC, which
has been primarily involved in the regulation of feeding rather
than energy expenditure (Williams and Elmquist, 2012; Yeo50 Cell Metabolism 20, 41–53, July 1, 2014 ª2014 Elsevier Inc.and Heisler, 2012), no effect was detected on BAT thermogenic
program. Likewise, genetic activation of AMPK within the VMH,
but not in the ARC, abolished the effect of central E2 on BAT pro-
gram markers. In contrast, genetic activation of AMPK in the
ARC reversed E2 anorectic action but had no effects on BAT
function.
Overall, these data confirm that E2 modulates energy homeo-
stasis in a brain site-specific fashion (Xu et al., 2011) and uncover
a molecular mechanism (i.e. modulation of AMPK, by which E2
specifically modulates BAT metabolism). Also, in agreement
with elegant studies from Clegg and colleagues (Heine et al.,
2000; Musatov et al., 2007; Xu et al., 2011), our data using phar-
macological and viral approaches also suggest that the effect of
E2 on the VMH AMPK-SNS-BAT axis is mediated by ERa.
Remarkably, physiological fluctuations in E2 levels during
estrous cycle and blockade of E2 actions also modulate the
aforementioned axis, indicating that this integrative response is
not a particular phenomenon restricted to conditions of estrogen
deficiency, such as OVX, but also a mechanism of relevance in
the physiological regulation of energy homeostasis by ovarian
estrogens.
In recent years, hypothalamic metabolic energy sensors, such
as AMPK, have been suggested to play a major role in the regu-
lation of energy homeostasis. Several metabolic hormones, such
as leptin, ghrelin, insulin, and thyroid hormones (Minokoshi et al.,
2004; Andrews et al., 2008; Lo´pez et al., 2008, 2010), and more
recently bone morphogenetic protein 8b (BMP8b) (Whittle et al.,
2012), have been shown to regulate energy balance acting
through those energy sensors. Here, we provide evidence that
E2, a hormone that markedly influences energy and metabolic
homeostasis, acts on the same sensors to control both feeding
and energy expenditure. Notably, the mechanisms described
here for the thermogenic actions of E2 display considerable
commonalities with those previously unveiled by our group for
thyroid hormone and BMP8b (Lo´pez et al., 2010; Whittle et al.,
2012). Thus, the VMH AMPK-SNS-BAT axis appears to act as
a canonical central mechanism integrating central and peripheral
regulation of energy stores. In this regard, our data points to
AMPK in the VMH as a potential target for the treatment of
obesity and other metabolic disorders associated to conditions
of endocrine deregulation. The relevance of such a pharmaco-
logical target is emphasized by recent reports showing that nico-
tine-induced anorexia and weight loss is in part mediated by
actions on AMPK-expressing neurons in the VMH to increase
energy expenditure (Martı´nez de Morentin et al., 2012), which
could be exploited as a potential therapeutic strategy. In addi-
tion, DiMarchi, Tschop, and colleagues have recently reported
an elegant approach based on the development of a combinato-
rial peptide of a glucagon-like peptide-1 (GLP-1)-estrogen con-
jugate for the treatment of obesity and metabolic syndrome
(Finan et al., 2012). They demonstrated that selective activation
of ERs in GLP-1-targeted tissues enhances the benefits of
both E2 andGLP-1 agonism on bodyweight, glucose homeosta-
sis, and lipid metabolism. Considering that both GLP-1 receptor
and ERa are highly expressed in the VMH (Shughrue et al., 1997;
Gu et al., 2013) raises the possibility that the metabolic benefits
of E2 and GLP-1 agonism may be mediated by selective modu-
lation of AMPK in the VMH. However, further investigations are
needed to test such possibility.
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VMH through ERa, which increases SNS tone, upregulates BAT
thermogenesis, and increases energy expenditure, leading to
weight loss. Thus, our data add more evidence to the fact that
AMPK, specifically in the VMH, is a canonical mechanismmodu-
lating energy dissipation via SNS activation of BAT. This obser-
vation provides insights into the physiological regulation of
energy balance and its perturbation in estrogen-deficient states
and suggests that the VMH AMPK-SNS-BAT axis may be a
potential therapeutic target for the treatment of obesity.
EXPERIMENTAL PROCEDURES
Animals
Female Sprague-Dawley and Wistar Unilever (for the microdialysis experi-
ments) rats (250–300 g; Animalario General USC, Santiago de Compostela,
Spain; Harlan, Horst, The Netherlands; and Charles River, Wilmington) were
used for the experiments. All animals were housed on a 12 hr light (8:00 to
20:00) 12 hr dark cycle, in a temperature- and humidity-controlled room. The
animals were allowed free access to standard laboratory pellets of rat chow
and tap water. The experiments were performed in agreement with the Inter-
national Law on Animal Experimentation and were approved by the USC Local
Ethical Committee and theMinistry of Science and Innovation of Spain (Project
ID PI12/01814), Animal Experimental Committee of the AMC, and the Univer-
sity of Iowa Institutional Animal Care and Use Committee.
OVX
Sprague-Dawley rats were bilaterally ovariectomized (OVX) or sham operated,
as described previously, under ketamine/xylacine anesthesia (50 mg/kg, intra-
peritoneally) (Vigo et al., 2007; Roa et al., 2009; Liu et al., 2013). All treatments
(central or peripheral) on OVX rats were carried out 2 weeks after surgery to
ensure a total washout of endogenous ovarian hormones. For the experiments
of E2 replacement, OVX rats received a daily SC injection of E2 (estradiol ben-
zoate; EB, 2 mg dissolved in 100 mL of sesame oil; both from Sigma; Saint
Louis) or vehicle (100 mL of sesame oil; control rats) during 7 days. EB was
chosen for SC administration, as this synthetic estrogen is endowed with
higher bio-potency and stability and it has been often used in various protocols
of peripheral estrogenization (Clegg et al., 2007; Roa et al., 2008).
Central and Peripheral Treatments
Chronic ICV cannulae were implanted as described previously (see Supple-
mental Experimental Procedures). We used 17b-estradiol (17b-E2, as the
major endogenous estrogen) in our central (ICV, VMH, or ARC) experiments in
amix DMSO:saline (1:10). Intact female (see below) or OVX rats were subjected
to a protocol of daily ICV injections of 17b-E2 (0.5 nmol, 1 nmol, or 5 nmol dis-
solved in 5 ml of saline containing 10% of DMSO; Sigma; Saint Louis) or vehicle
(5ml of saline containing10%ofDMSO;control rats) for 3–7days. For the exper-
iments of pharmacological AMPK activation, rats were ICV treated with AICAR
(5mgdissolved in 5ml of DMSO;Sigma, Saint Louis) or vehicle (5ml of DMSO), for
2 and 4 hr. For the experiments of ER stimulation of blockage, we used ICV
administration of the following: (a) the selective estrogen receptor alpha (ERa)
agonist PPT (1 nmol dissolved in 5 mL of saline containing 10% of DMSO;
TOCRIS Bioscience, Bristol) (Roa et al., 2008), (b) the combined ERa-b anta-
gonist named ICI 182.780 (2.5 nmol dissolved in 5 ml of saline containing 10%
of DMSO; TOCRIS Bioscience, Bristol) (Move´rare-Skrtic et al., 2014), (c) and
the specific ERa antagonistMPP (2.5 nmol dissolved in 5 ml of saline containing
10% of DMSO; TOCRIS Bioscience, Bristol) (Harrington et al., 2003). Both ICI
182.780 andMPP were administrated to intact female rats. The b3-AR specific
antagonist SR59230A (3 mg/kg/day; Tocris Bioscience, Bristol) (Lo´pez et al.,
2010) was administrated subcutaneously, starting during 2 days before the
ICV E2 injections. For more details of implantation of microdialysis probes
and central treatments, see Supplemental Experimental Procedures.
Stereotaxic Treatments of E2 and Viral Vectors
Freely moving rats were treated within the VMH or ARC with 17b-E2 (Sigma,
Saint Louis; 0.1 nmol in 1 ml of saline containing 10% of DMSO) or vehicle(1 ml of saline containing 10% of DMSO) during 2 or 12 hr. FITC (Sigma, Saint
Louis) was used to control the diffusion of the treatment. Adenoviral (GFP,
AMPKa-CA, or AMPKa-DN: Viraquest, North Liberty; ERa wildtype: Signagen;
Rockville) or lentiviral (GFP,ERa shRNA;SantaCruzBiotechnology;SantaCruz)
were stereotaxically delivered as previously reported (Lo´pez et al., 2008,
2010; Martı´nez de Morentin et al., 2012; Whittle et al., 2012; Schneeberger
et al., 2013). Animals were treated for 5–7 days in the case of adenoviruses
and16days in thecaseof lentiviruses,due to the longer infectiveperiodneeded.
Sample Processing and Analytical Methods
Sample processing, analysis of EE, LA, and RQ; nuclear magnetic resonance
analysis; sympathetic nerve activity (SNA) recording; temperature measure-
ments; E2, LH, and malonyl-CoA assays; and real-time quantitative PCR,
in situ hybridization, western blotting, and immunohistochemistry were per-
formed as previously shown (Lo´pez et al., 2008, 2010; Martı´nez de Morentin
et al., 2012; Whittle et al., 2012; Schneeberger et al., 2013) (see Supplemental
Experimental Procedures for detailed protocols).
Statistical Analysis
Data are expressed asmean ±SEM.mRNA and protein data were expressed in
relation (%) to control (vehicle-treated) rats. Error bars represent SEM. Statis-
tical significance was determined by Student’s t test when two groups were
compared or ANOVA and post hoc two-tailed Bonferroni test when more
than two groups were compared. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.03.031.
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